Diarylureas and Diarylamides with Oxazolo[5,4-d]pyrimidine Scaffold as Angiogenesis Inhibitors.

about

Diarylureas and Diarylamides with Oxazolo[5,4-d]pyrimidine Scaffold as Angiogenesis Inhibitors.

Item

http://www.wikidata.org/entity/Q51623284

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Diarylureas and Diarylamides w ...... ld as Angiogenesis Inhibitors.

@en

Diarylureas and Diarylamides w ...... ld as Angiogenesis Inhibitors.

@nl

type

Item

label

Diarylureas and Diarylamides w ...... ld as Angiogenesis Inhibitors.

@en

Diarylureas and Diarylamides w ...... ld as Angiogenesis Inhibitors.

@nl

prefLabel

Diarylureas and Diarylamides w ...... ld as Angiogenesis Inhibitors.

@en

Diarylureas and Diarylamides w ...... ld as Angiogenesis Inhibitors.

@nl

P1476

Diarylureas and Diarylamides w ...... ld as Angiogenesis Inhibitors.

@en

P2093

Ji-Ping Liu

http://www.w3.org/2001/XMLSchema#string

Li-Ping Sun

http://www.w3.org/2001/XMLSchema#string

Ya-Hui Deng

http://www.w3.org/2001/XMLSchema#string

Yi-Juan Cheng

http://www.w3.org/2001/XMLSchema#string

Yu Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced hepatocellular carcinoma

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Angiogenesis in cancer, vascular, rheumatoid and other disease

Angiogenesis: an organizing principle for drug discovery?

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.

Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.

P304

1230-1239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CBDV.201600035

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27448711

http://www.w3.org/2001/XMLSchema#string